BACKGROUND: The Centers for Medicare & Medicaid Services (CMS) mandate that every US hospital provide public online pricing information for services rendered. This allows patients to compare prices across hospital systems before establishing care. The goal of this project was to evaluate hospital compliance and patient-level accessibility to price transparency for common breast cancer surgical procedures. METHODS: A sample case of a 62-year-old female with a T2N0 breast cancer was chosen. The patient would have the option of undergoing a partial mastectomy or mastectomy, both with sentinel lymph node biopsy (SLNB). Eight Massachusetts academic medical centers were evaluated. Searches were performed by authors for each hospital system and procedure using the sample case. RESULTS: Every hospital had a cost calculator on its website. The average success rate of establishing a cost for partial mastectomy, mastectomy, and SLNB was 58, 35, and 25%, respectively. The median time to reach the cost calculator tool was 32 s (range 25-37 s). In successful attempts, the median pre-insurance estimated cost of a partial mastectomy was $16,509 (range $11,776-22,169), compared with $24,541 (range $16,921-25,543) for mastectomy and $12,342 (range $4034-20,644) for SLNB. SLNB costs varied significantly across hospitals (p = 0.025), but no statistically significant difference was observed for partial mastectomy or mastectomy. CONCLUSION: Despite new regulatory requirements by CMS for increased price transparency for surgical procedures, our results demonstrate poor success rates in obtaining cost estimates and significant variability of reported hospital charges. Further efforts to improve the quality of hospital cost estimate calculators are necessary for informed decision-making for patients with breast cancer.
References
Glennie RA, Barry SP, Alant J, Christie S, Oxner WM. Will cost transparency in the operating theatre cause surgeons to change their practice? J Clin Neurosci. 2019;60:1–6.
[DOI: 10.1016/j.jocn.2018.09.024]
Gupta R, Tsay C, Fogerty R. Promoting cost transparency to reduce financial harm to patients. AMA J Ethics. 2015;17(11):1073–8.
[DOI: 10.1001/journalofethics.2015.17.11.mhst1-1511]
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
[DOI: 10.3322/caac.21654]
Berlin NL, Chung KC, Matros E, Chen JS, Momoh AO. The costs of breast cancer reconstruction and implications for episode-based bundled payment models. Plast Reconstr Surg. 2020;146(6):721e–30e.
[DOI: 10.1097/PRS.0000000000007329]
Greenup RA, Rushing C, Fish L, et al. Financial costs and burden related to decisions for breast cancer surgery. J Oncol Pract. 2019;15(8):e666–76.
[DOI: 10.1200/JOP.18.00796]
Ehsan AN, Wu CA, Minasian A, et al. Financial toxicity among patients with breast cancer worldwide: a systematic review and meta-analysis. JAMA Netw Open. 2023;6(2):e2255388.
[DOI: 10.1001/jamanetworkopen.2022.55388]
Greenup RA. Financial toxicity and shared decision making in oncology. Surg Oncol Clin N Am. 2022;31(1):1–7.
[DOI: 10.1016/j.soc.2021.08.001]
Greenup RA, Rushing CN, Fish LJ, et al. Perspectives on the costs of cancer care: a survey of the American society of breast surgeons. Ann Surg Oncol. 2019;26(10):3141–51.
[DOI: 10.1245/s10434-019-07594-3]
De la Cruz Ku G, Karamchandani M, Chambergo-Michilot D, et al. Does breast-conserving surgery with radiotherapy have a better survival than mastectomy? A meta-analysis of more than 1,500,000 patients. Ann Surg Oncol. 2022;29:6163–88.
[DOI: 10.1245/s10434-022-12133-8]
Brill S. Bitter pill: why medical bills are killing us. Time. April 4, (2013) http://www.time.com/time/magazine/article/0,9171,2136864,00.html .
Carrera PM, Kantarjian HM, Blinder VS. The financial burden and distress of patients with cancer: understanding and stepping-up action on the financial toxicity of cancer treatment. CA Cancer J Clin. 2018;68(2):153–65.
[DOI: 10.3322/caac.21443]
Delgado-Guay M, Ferrer J, Rieber AG, et al. Financial distress and its associations with physical and emotional symptoms and quality of life among advanced cancer patients. Oncologist. 2015;20:1092–8.
[DOI: 10.1634/theoncologist.2015-0026]
Desai S, Hatfield L, Hicks A. Association between availability of a price transparency tool and outpatient spending. JAMA. 2016;315(17):1874–81.
[DOI: 10.1001/jama.2016.4288]
Higgins A, Brainard N, Veselovskiy G. Characterizing health plan price estimator tools: findings from a national survey. Am J Manag Care. 2016;22(2):126–31.
[PMID: 26885672]
Herb J, Williams B, Stitzenberg K. Hospital price transparency are inadequate to inform patients needing major gastrointestinal cancer operations. Ann Surg Oncol. 2022;29:45–6.
[DOI: 10.1245/s10434-021-10244-2]
Xiao R, Miller LE, Workman AD, Bartholomew RA, Xu LJ, Rathi VK. Analysis of price transparency for oncologic surgery among national cancer institute-designated cancer centers in 2020. JAMA Surgery. 2021;156(6):582–5.
[DOI: 10.1001/jamasurg.2021.0590]
Ayoub NF, Balakrishnan K. Price transparency and compliance with federal regulation for pediatric tonsillectomy. Otolaryngol Head Neck Surg. 2021;1945998211047146.
Agarwal A, Dayal A, Kircher SM, Chen RC, Royce TJ. Analysis of price transparency via national cancer institute-designated cancer centers’ chargemasters for prostate cancer radiation therapy. JAMA Oncol. 2020;6(3):409–12.
[DOI: 10.1001/jamaoncol.2019.5690]
Billig JI, Lan WC, Chung KC, Kuo CF, Sears ED. The increasing financial burden of outpatient elective surgery for the privately insured. Ann Surg. 2020;272(3):530–6.
[DOI: 10.1097/SLA.0000000000004201]
Linde S, Egede LE. Hospital price transparency in the United States: an examination of chargemaster, cash, and negotiated price variation for 14 common procedures. Med Care. 2022;60(10):768–74.
[DOI: 10.1097/MLR.0000000000001761]
Fu SJ, Rose L, Dawes AJ, et al. Out-of-pocket costs among patients with a new cancer diagnosis enrolled in high-deductible health plans vs traditional insurance. JAMA Netw Open. 2021;4(12):e2134282.
[DOI: 10.1001/jamanetworkopen.2021.34282]
